Revenue Breakdown
Composition ()
No data
Revenue Streams
Exagen Inc (XGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial, accounting for 54.8% of total sales, equivalent to $9.45M. Other significant revenue streams include Government and Client. Understanding this composition is critical for investors evaluating how XGN navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Exagen Inc maintains a gross margin of 58.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.98%, while the net margin is -41.10%. These profitability ratios, combined with a Return on Equity (ROE) of -122.81%, provide a clear picture of how effectively XGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, XGN competes directly with industry leaders such as BDSX and DCGO. With a market capitalization of $79.55M, it holds a significant position in the sector. When comparing efficiency, XGN's gross margin of 58.43% stands against BDSX's 81.14% and DCGO's 19.99%. Such benchmarking helps identify whether Exagen Inc is trading at a premium or discount relative to its financial performance.
